Sun Pharmaceutical Industries has secured investment-grade credit ratings from Moody’s and S&P for its pending $11.75 billion acquisition of Organon & Co. The deal, expected to close by early 2027, will be funded through a mix of internal cash and bridge financing. Investors are focusing on the strategic expansion into women’s health and biosimilars, while monitoring risks related to debt levels, integration challenges, and ongoing US FDA regulatory oversight.
Sun Pharmaceutical Industries has received a positive signal from major credit agencies as it prepares for its largest acquisition to date. Moody’s Ratings has assigned a 'Baa1' long-term issuer rating, and S&P Global Ratings has issued a preliminary 'BBB+' rating to the company. Both agencies have maintained a 'stable' outlook, which indicates that the company is expected to maintain its financial discipline even after taking on the significant debt required for the $11.75 billion purchase of Organon & Co.
Financing the Acquisition
The transaction is a massive undertaking that will require careful management of the balance sheet. To fund the $11.75 billion enterprise value, Sun Pharma has finalized a plan to use approximately $2 billion to $2.5 billion from its own cash reserves. The remaining amount, roughly $9.25 billion to $9.75 billion, will be raised through a bridge loan facility provided by a syndicate of international lenders. The investment-grade ratings are crucial here, as they help the company secure this funding at more favorable interest rates than it might otherwise receive.
Strategic Expansion Plans
The move is designed to shift Sun Pharma’s global position. By acquiring Organon, the company plans to gain a stronger foothold in two high-growth sectors: women’s health and biosimilars. Additionally, Organon’s existing infrastructure in markets like China and South Korea offers Sun Pharma a way to introduce its own product portfolio in regions where it has previously had limited influence. If the deal closes as expected by early 2027, analysts project that Sun Pharma could see its consolidated revenue grow to nearly $14 billion by fiscal year 2028.
Risks and Monitorables
While the expansion offers growth potential, investors should be aware of the complexities involved. Integrating a company of this size across more than 150 countries presents a major execution challenge. There is a risk that the actual savings or synergies from the merger may take longer to materialize than planned, which could pressure profit margins in the short term.
Furthermore, Sun Pharma has faced historical scrutiny from the US Food and Drug Administration (FDA) regarding some of its manufacturing facilities in India. Any regulatory delays or issues with product approvals could hinder the company's ability to maximize the value of the acquisition. Investors will likely track the company’s progress in securing final regulatory approvals for the deal, the successful integration of operations, and the management's ability to maintain a healthy debt-to-equity ratio as they repay the bridge financing.